Tonix Pharmaceuticals (TNXP) Projected to Post Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($3.23) per share and revenue of $2.55 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The firm had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $18.84 on Friday. The company has a market cap of $121.24 million, a P/E ratio of 0.00 and a beta of 1.63. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $17.99 and a 200 day moving average price of $20.71. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $672.00.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TNXP. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock. Noble Financial reissued an “outperform” rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.